Responsibility in Drug Advertising Act of 2025
Congress moves to block consumer ads for newly approved drugs for 3 years, with limited waiver option
Stalled
No legislative action in over 90 days.
Legislative Progress
Key Points
Impact Analysis
Personal Impact
How this policy affects specific groups of people
Milestones
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
2 articlesTrump announces crackdown on pharmaceutical advertising
White House memo directs tougher enforcement of existing direct-to-consumer drug ad rules, including on social media; related policy area but not this specific 3-year post-approval ban bill.
Senators Propose Ban on Drug Advertising to Consumers
Reports on senators proposing a broad ban on direct-to-consumer drug ads and references earlier legislation to restrict ads in the first three years after FDA approval (the same concept as this bill).
Source Information
Document Type
Congressional Bill
Official Title
Responsibility in Drug Advertising Act of 2025
Data Sources
Sponsor
Analysis generated by AI. Always verify with official sources.